



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q1

2026

ANDREAS NIEDERMAIER, CEO
ANDREAS LÖSLER, CFO

April 30, 2026

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q1 2026

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS


Positive start into the new year – all expectations met



Strong performance of previous year was surpassed once again:
+ 3% revenue growth
+ 18% EBITDA growth



Free float increased to nearly 75% leading to higher stock trading volumes



Ingredients in specialty chemicals driving volume growth



Carbide furnace overhaul on schedule
Recommissioning is expected in July 2026.



Group earnings strongly increased in Q1 2026 compared to previous year with 23% growth



Outlook confirmed;
Sales and EBITDA with growth potential in H2

PROJECTS - UPDATE

All Projects are essentially in line with expectations



Update on expansion projects

- ✓ Nitroguanidine 1:
Final construction activities in Germany; first test runs have begun
- ✓ Nitroguanidine 2:
US site search nearly finalized; Initial facility planning activities have already commenced
- ✓ Creatine:
Expansion program in Germany started, additional quantities expected in H2 2027

AGENDA – ANALYST PRESENTATION Q1 2026

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales and EBITDA reductions on expected level

SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q1
Volume	- 13.7%
Price	- 0.1%
Currency	- 0.2%

COMMENTS

- Sales decline mainly resulting from reduced quantities
- Most impact from ongoing weak economics within metallurgical sector in the European steel market and price pressure in the sectors agriculture and pharma
- Despite lower revenue, EBITDA remained at the previous year's level
- Inventories on December 2025 level as combination of reduced quantities and increased valuation



CREAMINO Dormex® Bioselect® **DYHARD®**  **Creapure®**

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality specialty chemical ingredients with strong growth perspectives.

SPECIALTY CHEMICALS SEGMENT (in M€)


Strong growth is supported by increased volumes and price increases




SALES



SALES




EBITDA



SALES ANALYSIS

	DELTA Q1
Volume	+ 6.4%
Price	+ 8.4%
Currency	- 3.3%

EBITDA



COMMENTS

- The substantial growth was mainly attributed to:
 - Human Nutrition** – Q4 2025 capacity expansion pays off - ongoing high demand for Creapure® and Creavitalis®
 - Defense** – High demand for Nitroguanidine, capacity expansion projects are on the way
 - Animal Nutrition** – Volume increase compared to the previous year, though price pressure from Chinese competitors
- EBITDA supported by high sales development with margin increase



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Regulated grid fees impact sales and result




SALES




SALES



EBITDA



EBITDA



COMMENTS

- Slight reduction in sales development compared to the previous year
- Sales & EBITDA development mainly resulting from reduced grid fee charges to chemical park customers

FINANCIAL OVERVIEW

All KPI above prior year – net income follows EBITDA growth



Alzchem Group

	Q1 2025	Q1 2026	qoq %
SALES (in M€)	144.7	148.7	+2.7%
EBITDA (in M€)	27.4	32.3	+18.0%
EBITDA margin (in %)	18.9%	21.7%	+2.8 pp
Earnings per Share (in €)	1.44	1.77	+22.9%

SALES ANALYSIS

Volume

DELTA Q1

-0,6%

Price

+5,6%

Currency

-2,2%

- Specialty Chemicals segment more than offsets declines in other segments – increase is driven by positive price and volume effects
- Reduced material expenses due to lower raw material usage resulting from different product mix
- Personnel expenses impacted by collective wage increases and slightly higher FTE following the growth programs
- Increased sales portion of Specialty Chemicals supports increase in EBITDA as well as EBITDA-margin
- Net result and EPS strongly increased and supported by EBITDA

BALANCE SHEET & CASHFLOW

Free Cashflow influenced by investments and customer grants



Balance sheet KPIs (T€)	31.12.2025	31.03.2026	Deviation	
Balance sheet total	617,679	654,476	36,797	6.0%
Inventories	116,004	122,576	6,572	5.7%
Equity	258,231	276,062	17,831	6.9%
Equity ratio	41.8%	42.2%	0.4 pp	
Liabilities to Banks	41,118	39,506	- 1,612	-3.9%
Cash and cash equivalents	71,720	69,347	- 2,374	-3.3%
Net financial debt (-) / asset (+)	30,602	29,841	- 762	-2.5%

Cashflow KPIs (T€)	1 - 3 2025	1 - 3 2026	Deviation	
Operating Cashflow	49,517	37,667	- 11,850	-23.9%
Investing Cashflow	- 13,101	- 36,565	- 23,464	179.1%
Free Cashflow	36,415	1,102	- 35,313	-97.0%
Financial Cashflow	- 6,461	- 3,534	2,927	45.3%
Net increase in cash	29,955	2,432	- 32,387	-108.1%

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX
- Net financial assets at balance sheet date
- Reduced operating cashflow results from lower customer grants for capex program
 - EUR 39,5m in Q1 2025
 - EUR 5,9m in Q1 2026
- Investing cashflow highly above prior year as Nitroguanidine expansion is on schedule
- Free cash flow still positive despite huge investments
- Pension obligation on reduced level as interest rates increased to 4.2%

KPI impact of nitroguanidine expansion in total on balance sheet in M€




OUTLOOK 2026 (in M€)


Ongoing growth in sales and EBITDA despite high investments



SALES



EBITDA



COMMENTS

Outlook for 2026 confirmed

Major assumptions are still valid

- No significant impact of the Iran conflict; long-term disruption of global supply chains is not included in the outlook
- Possible cost increases shall be passed through to customers
- First quantities from new NQ-plant will be delivered in H2 2027

Sales Growth

- Growth mainly coming from ingredients in segment Specialty Chemicals
- Basics & Intermediates: Sales remain on previous year's level. Potential negative impact by quantity losses due to abandonment of low-price business
- Organic growth, no acquisitions

EBITDA Growth

- Further increase in higher-margin specialty chemical sales will increase EBITDA as well
- Impact from carbide furnace maintenance as expected

FINANCIAL CALENDAR

Upcoming dates*



MAY 5	2026	Annual General Meeting 2026
MAY 20-21	2026	Berenberg European Conference, Manhattan
MAY 27	2026	Kepler Cheuvreux Virtual SMID CEO-CFO Week, Virtual
JUL 30	2026	Half-year Financial Report 2026
SEP 8	2026	Berenberg Food Ingredients & Chemicals Conference, London
OCT 29	2026	Quarterly Statement 3rd Quarter 2026
NOV 23-24	2026	Deutsches Eigenkapitalforum, Frankfurt
DEC 10	2026	MPCM Exclusive Company Evening, Frankfurt

*subject to change

ALL DATES AT A
GLANCE

 [Financial calendar](#)



FEEDBACK

We appreciate your feedback



Were your expectations met?
Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q1 2026

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

KPI IMPACT OF CUSTOMER GRANTS

Timing and effects on balance sheet and P&L



KPI EFFECTS

2025/2026

Cash / Assets



Other receivables



Equity



Contract liabilities



Equity ratio



Sales



EBITDA



KPI EFFECTS

2027 et seq.

Cash / Assets



Other receivables



Equity



Contract liabilities



Equity ratio




Sales



EBITDA




EST KEY EFFECTS ¹



TOTAL EFFECTS in M€



EST CASH ²



1) Only customer investment contribution / 2) Based on our current best estimate and ongoing negotiations

BALANCE SHEET

Alzchem Group



ALZCHEM GROUP (IN T€)

	31.12.2025	31.03.2026	Deviation	
Intangible assets	3,530	3,849	319	9.0%
Tangible assets	276,980	299,002	22,022	8.0%
Investment properties				
Right of use (assets)	2,992	2,561	-431	-14.4%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	21,801	18,790	-3,011	-13.8%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	15,711	14,617	-1,094	-7.0%
SUM NON-CURRENT ASSETS	321,019	338,824	17,805	5.5%
Inventories	116,004	122,576	6,572	5.7%
Trade receivables	73,416	86,276	12,860	17.5%
Financial assets	0	0	0	-14.5%
Other receivables	35,201	37,436	2,235	6.3%
Income tax receivables	319	17	-302	-94.6%
Cash and cash equivalents	71,720	69,347	-2,374	-3.3%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	296,660	315,652	18,992	6.4%
SUM ASSETS	617,679	654,476	36,797	6.0%

ALZCHEM GROUP (IN T€)

	31.12.2025	31.03.2026	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	232,111	250,069	17,958	7.7%
Other comprehensive income	-12,398	-11,268	1,130	-9.1%
Own shares	-4,111	-5,411	-1,300	31.6%
SHARE TO THE SHAREHOLDERS	256,296	274,085	17,788	6.9%
Non-controlling interests	1,934	1,977	43	2.2%
SUM EQUITY	258,231	276,062	17,831	6.9%
Provisions for pensions	88,239	87,089	-1,150	-1.3%
Other provisions	18,981	19,269	288	1.5%
Loans	34,750	33,166	-1,583	-4.6%
Finance lease liabilities	1,239	837	-402	-32.5%
Trade liabilities	14		-14	-100.0%
Contract liabilities	88,099	89,484	1,385	1.6%
Other liabilities	492	321	-171	-34.7%
Deferred tax liabilities	8,730	8,799	69	0.8%
SUM NON-CURRENT LIABILITIES	240,543	238,965	-1,578	-0.7%
Other provisions	7,190	4,492	-2,698	-37.5%
Loans	6,368	6,340	-29	-0.5%
Finance lease liabilities	1,874	1,843	-31	-1.7%
Finance liabilities				
Trade liabilities	51,726	74,535	22,809	44.1%
Contract liabilities	2,433	4,658	2,225	91.5%
Other liabilities	38,340	34,713	-3,626	-9.5%
Income tax liabilities	10,973	12,868	1,895	17.3%
SUM CURRENT LIABILITIES	118,904	139,449	20,544	17.3%
Sum EQUITY AND LIABILITIES	617,679	654,476	36,797	6.0%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 4.1% to 4.2%
- Pension payments develop as expected with 0.8 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026	Deviation (Q1)	
Revenue	144,680	142,879	137,266	137,290	148,653				3,973	3%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	11,436	3,433	624	545	4,143				-7,294	-64%
Other income	5,263	5,006	3,806	9,266	7,339				2,076	39%
Raw materials and consumables used	-64,236	-47,293	-43,769	-42,989	-53,148				11,087	-17%
Employee benefits expense	-41,150	-44,894	-43,245	-44,322	-44,117				-2,967	7%
Other expense	-28,632	-30,036	-24,957	-29,494	-30,583				-1,951	7%
EBITDA	27,362	29,096	29,724	30,296	32,286				4,924	18%
Depreciation expense	-6,552	-6,435	-6,655	-7,007	-6,701				-149	2%
Impairment										
EBIT	20,810	22,662	23,069	23,290	25,585				4,775	23%
Investment income										
Other interest and similar income	712	626	819	1,082	381				-330	-46%
Other interest and similar expense	-1,278	-1,284	-1,254	-1,314	-1,330				-51	4%
Financial result	-567	-658	-436	-232	-948				-382	67%
Result from associates										
Result from ordinary business	20,243	22,003	22,634	23,057	24,637				4,393	22%
Taxes on income and profit	-5,607	-6,128	-6,297	-6,276	-6,636				-1,029	18%
<i>thereof income tax</i>	-4,537	-6,330	-5,550	-6,040	-5,754				-1,217	27%
<i>thereof change from deferred taxes</i>	-1,070	202	-748	-235	-882				188	-18%
Annual result	14,636	15,876	16,337	16,782	18,001				3,364	23%
<i>thereof minority interests</i>	43	43	43	43	43					
<i>thereof shares held by shareholders</i>	14,594	15,833	16,294	16,739	17,958				3,364	23%
Result per share in EUR	1.44 €	1.57 €	1.61 €	1.66 €	1.77 €					

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

	Q1 2025	Q1 2026	Deviation (QoQ)		YTD Mrz.2025	YTD Mrz.2026	Deviation (YoY)	
Revenue	144,680	148,653	3,973	2.7%	144,680	148,653	3,973	2.7%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	11,436	4,143	-7,294	-63.8%	11,436	4,143	-7,294	-63.8%
Other income	5,263	7,339	2,076	39.4%	5,263	7,339	2,076	39.4%
Raw materials and consumables used	-64,236	-53,148	11,087	-17.3%	-64,236	-53,148	11,087	-17.3%
Employee benefits expense	-41,150	-44,117	-2,967	7.2%	-41,150	-44,117	-2,967	7.2%
Other expense	-28,632	-30,583	-1,951	6.8%	-28,632	-30,583	-1,951	6.8%
EBITDA	27,362	32,286	4,924	18.0%	27,362	32,286	4,924	18.0%
Depreciation expense	-6,552	-6,701	-149	2.3%	-6,552	-6,701	-149	2.3%
Impairment	0	0	0		0	0	0	
EBIT	20,810	25,585	4,775	22.9%	20,810	25,585	4,775	22.9%
Investment income	0	0	0		0	0	0	
Other interest and similar income	712	381	-330	-46.4%	712	381	-330	-46.4%
Other interest and similar expense	-1,278	-1,330	-51	4.0%	-1,278	-1,330	-51	4.0%
Financial result	-567	-948	-382	67.3%	-567	-948	-382	67.3%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	20,243	24,637	4,393	21.7%	20,243	24,637	4,393	21.7%
Taxes on income and profit	-5,607	-6,636	-1,029	18.4%	-5,607	-6,636	-1,029	18.4%
<i>thereof income tax</i>	-4,537	-5,754	-1,217	26.8%	-4,537	-5,754	-1,217	26.8%
<i>thereof change from deferred taxes</i>	-1,070	-882	188	-17.6%	-1,070	-882	188	-17.6%
Annual result	14,636	18,001	3,364	23.0%	14,636	18,001	3,364	23.0%
<i>thereof minority interests</i>	43	43	0	0.0%	43	43	0	0.0%
<i>thereof shares held by shareholders</i>	14,594	17,958	3,364	23.1%	14,594	17,958	3,364	23.1%
Result per share in EUR	1.44 €	1.77 €	0	22.9%	1.44 €	1.77 €	0	22.9%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	1 - 3 2025	1 - 3 2026
Consolidated earnings before taxes	20,243	24,637
Depreciation on fixed and intangible assets	6,552	6,701
Decrease in pension provisions	-768	-832
Loss (+) / Profit (-) from the sale of non-current assets	22	-27
Other non-cash income (-) and expenses (+)	272	2,324
Financial result	567	948
Interests & Taxes	-3,748	-5,018
Increase (+) / Decrease (-) Net Working Capital	-13,124	2,961
Payments from customer grants	39,501	5,973
Cashflow from ongoing operations (Net cash flow)	49,517	37,667
Cash outflows for investments in fixed assets	-13,141	-36,599
Cash inflows from the sale of fixed assets	40	35
Cash inflows from grants received for investments		
Cashflow from investing activity	-13,101	-36,565
Free cashflow	36,415	1,102
Deposits (+) / Repayment (-) bank loans long-term		
Repayment of bank loans long-term	-2,208	-1,583
Deposits (+) / Repayment (-) from short-term financing lines		
Dividend payments		
Payment of reduction in leasing liabilities	-478	-478
Payments for the acquisition of own shares (incl. transaction costs)	-3,604	-1,300
Payments for the issue of own shares		-1
Payments to non-controlling interests	-171	-171
Cashflow from financing activity	-6,461	-3,534

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

SALES	2024				2025				2026				Deviation PY (Q1)		YTD Q1 2026		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	49,299	41,848	40,927	41,929	42,638	35,605	43,309	33,539	36,666				-5,972	-14%	42,638	36,666	-5,972	-14%
Specialty Chemicals	92,961	85,805	80,354	88,969	94,512	100,128	86,978	97,159	105,298				10,786	11%	94,512	105,298	10,786	11%
Other and Holding	7,804	8,538	7,656	8,142	7,530	7,146	6,979	6,592	6,689				-841	-11%	7,530	6,689	-841	-11%
<i>Group Consolidation</i>																		
Alzchem Group	150,064	136,191	128,937	139,040	144,680	142,879	137,266	137,290	148,653				3,973	3%	144,680	148,653	3,973	3%

EBITDA

EBITDA	2024				2025				2026				Deviation PY (Q1)		YTD Q1 2026		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	1,802	3,055	1,827	4,142	140	1,174	3,754	549	284				144	103%	140	284	144	103%
Specialty Chemicals	22,684	22,843	21,749	26,741	26,041	27,854	24,117	28,782	31,484				5,444	21%	26,041	31,484	5,444	21%
Other and Holding	537	849	1,114	-711	307	50	596	-287	222				-86	-28%	307	222	-86	-28%
<i>Group Consolidation</i>	-113	274	194	-1,717	874	18	1,257	1,253	296				-578	-66%	874	296	-578	-66%
Alzchem Group	24,910	27,021	24,883	28,455	27,362	29,096	29,724	30,296	32,286				4,924	18%	27,362	32,286	4,924	18%

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



- SALES COMPANY
- PRODUCTION SITE


Production facilities in Germany (4) and Sweden (1) and HQ in Trostberg (GER)

"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



- Segment Specialty Chemicals
- Segment Basics & Intermediates



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS



POPULATION GROWTH



LONGER LIFE EXPECTANCY



CLIMATE CHANGE



SUSTAINABILITY



SAFETY & DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries






	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense	

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ[®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	<p>Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)</p> <p>Site services</p> <p>Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments</p>		


KEY SHARE DATA

Share details as of April 29, 2026



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 174.30
MARKET CAPITALIZATION	EUR 1,774 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
STOCK MARKET SEGMENT	SDAX since October 2, 2024
DESIGNATED SPONSOR	LBBW ODDO BHF SE

SHAREHOLDER STRUCTURE



As of January 2026. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."